BioLamina
Cell-specific culture matrices for improve cell functionality
- 101-200 employees
- Healthcare
- B2B
- Biology
- eCommerce
- MedTech
- Lilla Alby, Sundbyberg, Stockholm County
Jump to section
Company mission
To become the leading provider of primary cell culture solutions to enable life-saving therapies.
Our take
Cell culture is the base research of basic cell biology to replicate disease mechanisms, or investigate the toxicity of novel drug compounds. Created by a father-son team BioLamina is a biotech company contributing to the global health movement. Its mission is to foster expertise in the development and production of recombinant human laminins (key proteins enabling researchers and biopharma to grow, manipulate, and engineer both stem cells and certain primary cells). A feat that has previously been a struggle for scientists.
The company has created a product collection of cell culture matrices that can be used for culture applications and research, these products are now being sold to academic and industrial scientists globally. A turning point in early 2023 was the opening of a new premises scaling BioLamina’s product production and responding to growing demand.
With recent funding, the company is gearing up expand its development of laminin technology, enabling next-generation cell therapies and more advanced, animal-free methods for drug safety testing.
Steph
Company Specialist at Welcome to the Jungle
Funding (last 2 of 4 rounds)
Sep 2023
$19.6m
EARLY VC
Oct 2021
$4.1m
EARLY VC
Total funding: $24.7m
Leadership
Klaus Langhoff-Roos
(CEO)Klaus is also a Board Member at Stimuliver. Previously, they were the CEO of StemMedical and spent 18 years at Novo Nordisk in various roles, including Corporate VP of Cell Therapy Commercial.